Views & Analysis Addressing MS’ two-tier healthcare system is about ‘social j... NICE has reversed its decision not to approve a new drug that offers hope to thousands o
Views & Analysis Listening to the Patient Voice: seek out the quietest voice ... The success or failure of patient centricity rests on getting the patient voice in the mix – not just listening to those who shout the loudest.
Views & Analysis Case study: Ensuring safety by digitally linking prescriptio... Monitoring people who are on disease modifying drugs (DMDs) is paramount to providing safe, high-quality MS care.
Views & Analysis Addressing the growing need for better Multiple Sclerosis ca... Jo Sopala of the MS Trust describes the organisation's work in creating better multiple sclerosis care.
News Otsuka eyes early filing of IgAN drug after phase 3 readout Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.